Welcome to our dedicated page for Sagimet Biosciences SEC filings (Ticker: SGMT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Sagimet Biosciences Inc. (NASDAQ: SGMT) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Sagimet is a clinical-stage biopharmaceutical company developing oral fatty acid synthase (FASN) inhibitors for metabolic and fibrotic diseases, and its filings offer detailed insight into this development strategy, capital structure, and risk profile.
Through Forms 8-K, Sagimet reports material events such as clinical trial updates, license agreements, accounting firm changes, at-the-market equity sales arrangements, and quarterly financial results. For example, recent 8-K filings describe positive Phase 1 pharmacokinetic data for a denifanstat and resmetirom combination, a global license agreement with TAPI for innovative forms of resmetirom active pharmaceutical ingredient to support a fixed-dose combination program, and financial results for recent quarters. Other 8-Ks outline changes in the company’s independent registered public accounting firm and the establishment of an at-the-market offering program for its Series A common stock.
Investors and analysts can use this page to locate Sagimet’s periodic and current reports, including annual reports on Form 10-K and quarterly reports on Form 10-Q when available, which typically contain information on clinical development progress for denifanstat and TVB-3567, funding arrangements, and risk factors related to MASH and acne programs. Forms 4 and other ownership-related filings, when present, can be used to monitor insider transactions in SGMT shares.
Stock Titan enhances these filings with AI-powered summaries that explain the key points of lengthy documents, helping readers quickly understand the significance of new 10-Ks, 10-Qs, and 8-Ks. Real-time updates from EDGAR ensure that new Sagimet filings appear promptly, while AI-generated highlights can clarify complex topics such as licensing terms, at-the-market sales agreements, and clinical trial disclosures. This makes the SGMT filings page a practical starting point for reviewing Sagimet’s regulatory history and ongoing obligations.
Sagimet Biosciences (SGMT) furnished an updated investor presentation as Exhibit 99.1 to a Form 8-K. The company states that the materials in Item 7.01 and Exhibit 99.1 are being furnished and are not deemed filed under Section 18 of the Exchange Act, nor incorporated by reference except as expressly set forth in a future filing.
Representatives may use the updated presentation in meetings with investors from time to time. The filing is an informational Reg FD update and does not announce a transaction or financial results.
Sagimet Biosciences Inc. reported that its Board of Directors, following a recommendation from the Audit Committee, approved a change in independent auditors. Effective August 18, 2025, KPMG LLP was appointed as the company’s independent registered public accounting firm for the fiscal year ending December 31, 2025 and related interim periods, and Deloitte & Touche LLP was dismissed from this role.
The company states that Deloitte’s audit reports on the financial statements for the years ended December 31, 2024 and 2023 contained no adverse opinions, disclaimers of opinion, or qualifications, and that there were no disagreements with Deloitte on accounting principles, financial statement disclosure, or audit procedures during those periods and through August 18, 2025. Sagimet also notes that during the same periods it did not consult KPMG on specific accounting transactions or anticipated audit opinions before this appointment.
Sagimet Biosciences Inc. (Series A Common Stock, CUSIP 786700104) is the subject of an amended Schedule 13G filed by Point72 Asset Management, L.P., Point72 Capital Advisors, Inc., and Steven A. Cohen reporting ownership information as of June 30, 2025. The filing states that each reporting person beneficially owns 0 shares and 0% of the Series A common stock and reports no sole or shared voting or dispositive power. The filing includes the issuer address and identifies the filers and their Delaware organization or U.S. citizenship where applicable. The submission contains a certification that the shares were not acquired to influence control of the issuer.
Sagimet Biosciences, Inc. reported the entry into a material definitive agreement on August 14, 2025. The filing lists a Sales Agreement dated August 14, 2025 between Leerink Partners LLC and Sagimet Biosciences Inc., and includes an opinion from Goodwin Procter LLP and their consent. The document is an 8-K disclosing a material transaction; no financial terms, offering amounts, or other operational details are provided in the text supplied.
Sagimet Biosciences Inc. filed a prospectus supplement to offer up to $75.0 million of Series A common stock through an "at-the-market" sales agreement with Leerink Partners. The company’s Series A common stock trades on Nasdaq under the symbol SGMT and the last reported sale price referenced was $9.58 per share on August 13, 2025. Net proceeds are intended to advance development of denifanstat and other FASN inhibitors, for R&D, working capital and general corporate purposes.
The supplement highlights clinical progress: denifanstat met both primary and multiple secondary endpoints in a Phase 2b FASCINATE-2 MASH trial (statistically significant histologic and MRI-PDFF results) and received FDA Breakthrough Therapy designation for non-cirrhotic MASH F2-F3. Ascletis reported positive Phase 3 acne results for denifanstat in China. Sagimet is exploring Phase 3 funding and will initiate a Phase 1 PK study of denifanstat plus resmetirom in H2 2025, and started a Phase 1 trial of second candidate TVB-3567 in June 2025.
Woodline Partners LP disclosed beneficial ownership of 2,552,536 shares of Sagimet Biosciences Series A common stock, representing approximately 8.3% of the outstanding class. The shares are directly held by Woodline Master Fund LP, for which Woodline Partners serves as investment adviser, and the reporting page shows Woodline Partners has sole voting and dispositive power over these shares.
The filing was made on Schedule 13G and includes a certification that the securities were acquired and are held in the ordinary course of business and were not purchased to change or influence control of the issuer. The percentage is calculated using an aggregate share base of about 30,674,855 shares reported in the company’s quarterly report for the period ended March 31, 2025.
Sagimet Biosciences announced it has furnished a press release reporting its financial results for the quarter ended June 30, 2025 and has updated its investor slide presentation. The press release is furnished as Exhibit 99.1 and the slide deck as Exhibit 99.2.
Both exhibits are described in the report as being furnished rather than filed, and therefore are not deemed filed or incorporated by reference into other SEC filings except if expressly referenced. Company representatives will use the updated presentation in meetings with investors.
Sagimet Biosciences (SGMT) is a clinical-stage biopharmaceutical company developing FASN inhibitors led by denifanstat. The company reported strong clinical progress: its Phase 2b FASCINATE-2 trial in MASH achieved both primary endpoints with statistically significant histologic and biomarker improvements, and denifanstat received FDA Breakthrough Therapy designation for non-cirrhotic MASH with F2-F3 fibrosis. License partner Ascletis reported denifanstat met all primary and secondary endpoints in a Phase 3 acne trial and plans submission in China.
Financially, Sagimet had $135.5 million of cash, cash equivalents and marketable securities as of June 30, 2025 and expects these funds to support operations for at least 12 months. R&D spend rose sharply as programs advanced: six-month R&D expense was $22.59 million (up 95% year-over-year). Net loss for six months was $28.56 million, and the company had an accumulated deficit of $323.9 million. TVB-3567 received IND clearance in March 2025 and a first-in-human Phase 1 trial began in June 2025.